HCM
TVRD

Highbridge Capital Management’s Tvardi Therapeutics TVRD Stock Holding History

Highbridge Capital Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-289
Closed -$142K – 2022
2017
Q3 		$142K Buy
+289
New +$145K ﹤0.01% 1454

Other funds holding TVRD

RCP
Rho Capital Partners New York $20.4M AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Highbridge Capital Management's TVRD Position: Q4 2016 in Review

Highbridge Capital Management sold out of Tvardi Therapeutics (TVRD) in Q4 2016, closing a stake of 348 shares — an estimated $105K sold.

Highbridge Capital Management first reported a position in TVRD in Q1 2015 and held it in 6 quarters. The position peaked at $638K in Q4 2015. 101 funds tracked by Wall St. Rank hold TVRD as of Q4 2016.

  • Highbridge Capital Management reported no remaining Tvardi Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Highbridge Capital Management sold 348 Tvardi Therapeutics shares in Q4 2016, an estimated $105K.
  • Highbridge Capital Management first reported a position in Tvardi Therapeutics in Q1 2015 and held it in 6 quarters.
  • Highbridge Capital Management's Tvardi Therapeutics position peaked at $638K in Q4 2015.
  • 101 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2016.

Based on Highbridge Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.